The role of COX-2 inhibitors in pain modulation

Drugs

Volumn 63, Issue SUPPL. 1, 2003, Pages 1-7

  Camu, Frederic ^a,b   Shi, Lin ^a   Vanlersberghe, Caroline ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GABAPENTIN; IBUPROFEN; KETAMINE; KETOROLAC; LOCAL ANESTHETIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; TRICYCLIC ANTIDEPRESSANT AGENT;

CONFERENCE PAPER; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HYPERALGESIA; NOCICEPTION; PAIN;

EID: 0038384094     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363001-00002     Document Type: Conference Paper

References (49)

1. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-8
2. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410: 471-5
3. Baba H, Kohno T, Moore KA, et al. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001; 21: 1750-6
4. Cashman JN. The mechanism of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl. 5: 13-23
5. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res 2000; 2: 379-85
6. Woolf CJ, Thompson S. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293-9
7. Beiche F, Scheurer S, Brune K, et al. Upregulation of COX-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996; 390: 165-9
8. Sorkin LS, Xiao WH, Wagner R, et al. Tumor necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibers. Neuroscience 1997; 81: 255-62
9. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNF-α. Pain 2000; 85: 145-51
10. Laflamme N, Lacroix S, Rivest S. An essential role of interleukin-1 beta in mediating NF-κB activity and COX-2 transcription in cells of the blood brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999; 19: 10923-30
11. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002; 8: 390-6
12. Matsumura K, Cao C, Ozaki M, et al. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: light and electron microscopic immunocytochemical studies. J Neurosci 1998; 18 Suppl 16: 6279-89
13. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998; 15: 13313-8
14. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276-9
15. Hinz B, Brune K. Cyclooxygenase-2 - 10 years later. J. Pharmacol Exp Ther 2002; 300: 367-75
16. Willingale HL, Gardiner NJ, Mclymont N, et al. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 1997; 122: 1593-1604
17. 2α primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons. Pain 2002; 97: 33-45
18. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9-43
19. Quattrini M, Paladin S. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthrosis of the hip. Clin Drug Invest 1995; 10: 139-46
20. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis. A six month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 Suppl. 1: 39-43
21. Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. J. Rheumatol 1997; 24 Suppl.47: 10-16
22. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: double-blind comparison. Lancet 1999; 354: 2106-11
23. Bombardier C, Laine L, Reicin A, et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
24. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-55
25. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8
26. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33
27. Ormrod D, Wellington K, Wagstaff AJ. Valdecoxib. Drugs 2002; 62: 2059-71
28. Vane JR. Towards a better aspirin. Nature 1994; 367: 215-6
29. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10
30. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997; 18: 30-4
31. van Ryn J, Pairet M. Clinical experience with cyclooxygenase-2 inhibitors. Inflamm Res 1999; 48: 247-54
32. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8
33. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenase. Arzneimittel Forschung 1995; 45: 1093-5
34. Grossman CJ, Wiseman J, Lucas FS, et al. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflamm Res 1995; 44: 253-7
35. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997; 46: 437-46
36. Fitzgerald D, McCrory C. Pharmacology of COX-2 inhibition in man. Anti-inflammatory and analgesic effects of nimesulide. Drugs Today 2001; 37 Suppl B: 15-20
37. Bevilacqua M, Vago T, Beretta A. Nimesulide as inhibitor of superoxide anions (O2-) production by human polymorphonuclear leucocytes. Pain Reproduct 1988; 31: 265-72
38. Casolaro V, Meliota S, Marino O, et al. Nimesulide, a sulfoanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophiles and mast cells. J Pharmacol Exp Ther 1994; 267: 1375-85
39. Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46 Suppl 1: 1-9
40. Di Battista JA, Fahmi H, He Y, et al. Differential regulation of interleukin-1b-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts. Clin Exp Rheumatol 2001; 19 Suppl 22: 3-5S
41. Bennett A, Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277-86
42. Bevilacqua M, Vago T, Baldi G, et al. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268: 415-23
43. Capecchi PL, Ceccatelli L, Beermann U, et al. Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine mediated mechanism. Arzneimittel Forschtmg 1993; 43: 992-6
44. Azab A, Fraifeld V, Kaplanski J. Nimesulide prevents lipopolysaccharide-induced elevation in plasma tumor necrosis factor-alfa in rats. Life Sci 1998; 63: 323-7
45. Bennett A. Nimesulide: awell-established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Vane J, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001: 524-40
46. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology 1999; 38 Suppl. 1: 33-8
47. Rainsford KD. An analysis from clinico-epidemiological data of the principal adverse events from COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury. Inflammopharmacology 1998; 6: 203-21
48. McCormack KJ, Brune K. Dissociation between the anti-nociceptive and anti-inflammatory effects of the non-steroidal anti-inflammatory drugs: a survey of their analgesic efficacy. Drugs 1991; 41: 533-47
49. Voilley N, de Weille J, Mamet J, et al. Nonsteroidal anti-inflammatory drugs inhibit both the activity and inflammation-induced expression of acid-sens in ion channels in nociceptors. J Neurosci 2001; 21: 8026-33